U.S. markets open in 5 hours 42 minutes
  • S&P Futures

    4,172.25
    +12.25 (+0.29%)
     
  • Dow Futures

    34,202.00
    +84.00 (+0.25%)
     
  • Nasdaq Futures

    13,554.50
    +63.50 (+0.47%)
     
  • Russell 2000 Futures

    2,247.60
    +11.00 (+0.49%)
     
  • Crude Oil

    65.88
    +0.25 (+0.38%)
     
  • Gold

    1,793.00
    +8.70 (+0.49%)
     
  • Silver

    26.84
    +0.32 (+1.22%)
     
  • EUR/USD

    1.2032
    +0.0023 (+0.19%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • Vix

    18.30
    -1.18 (-6.06%)
     
  • GBP/USD

    1.3905
    -0.0003 (-0.02%)
     
  • USD/JPY

    109.3270
    +0.1380 (+0.13%)
     
  • BTC-USD

    56,687.12
    +1,915.45 (+3.50%)
     
  • CMC Crypto 200

    1,454.62
    +49.31 (+3.51%)
     
  • FTSE 100

    7,063.03
    +23.73 (+0.34%)
     
  • Nikkei 225

    29,331.37
    +518.77 (+1.80%)
     

Annual Changes to the Nasdaq Biotechnology Index

  • Oops!
    Something went wrong.
    Please try again later.
Nasdaq, Inc.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 100 securities will be added to the Index:

EXCHANGE

SYMBOL

COMPANY NAME

Nasdaq

ABUS

Arbutus Biopharma Corporation

Nasdaq

ADAP

Adaptimmune Therapeutics plc

Nasdaq

AKUS

Akouos, Inc.

Nasdaq

ALT

Altimmune, Inc.

Nasdaq

ALVR

AlloVir, Inc.

Nasdaq

ALXO

ALX Oncology Holdings Inc.

Nasdaq

AMTI

Applied Molecular Transport Inc.

Nasdaq

ANNX

Annexon, Inc.

Nasdaq

APLT

Applied Therapeutics, Inc.

Nasdaq

APRE

Aprea Therapeutics, Inc.

Nasdaq

ARCT

Arcturus Therapeutics Holdings Inc.

Nasdaq

ARQT

Arcutis Biotherapeutics, Inc.

Nasdaq

AVDL

Avadel Pharmaceuticals plc

Nasdaq

AZN

AstraZeneca PLC

Nasdaq

BDTX

Black Diamond Therapeutics, Inc.

Nasdaq

BEAM

Beam Therapeutics Inc.

Nasdaq

BNTX

BioNTech SE

Nasdaq

CABA

Cabaletta Bio, Inc.

Nasdaq

CALA

Calithera Biosciences, Inc.

Nasdaq

CDXS

Codexis, Inc.

Nasdaq

CLVS

Clovis Oncology, Inc.

Nasdaq

CNCE

Concert Pharmaceuticals, Inc.

Nasdaq

CNST

Constellation Pharmaceuticals, Inc.

Nasdaq

CRNX

Crinetics Pharmaceuticals, Inc.

Nasdaq

CRTX

Cortexyme, Inc.

Nasdaq

FMTX

Forma Therapeutics Holdings, Inc.

Nasdaq

FPRX

Five Prime Therapeutics, Inc.

Nasdaq

FREQ

Frequency Therapeutics, Inc.

Nasdaq

FULC

Fulcrum Therapeutics, Inc.

Nasdaq

FUSN

Fusion Pharmaceuticals Inc.

Nasdaq

GBIO

Generation Bio Co.

Nasdaq

GMDA

Gamida Cell Ltd.

Nasdaq

HARP

Harpoon Therapeutics, Inc.

Nasdaq

IDYA

IDEAYA Biosciences, Inc.

Nasdaq

IGMS

IGM Biosciences, Inc.

Nasdaq

IMAB

I-MAB

Nasdaq

IMUX

Immunic, Inc.

Nasdaq

IMVT

Immunovant, Inc.

Nasdaq

INZY

Inozyme Pharma, Inc.

Nasdaq

ISEE

IVERIC bio, Inc.

Nasdaq

ITOS

iTeos Therapeutics, Inc.

Nasdaq

JNCE

Jounce Therapeutics, Inc.

Nasdaq

KALA

Kala Pharmaceuticals, Inc.

Nasdaq

KALV

KalVista Pharmaceuticals, Inc.

Nasdaq

KDMN

Kadmon Holdings, Inc.

Nasdaq

KDNY

Chinook Therapeutics, Inc.

Nasdaq

KLDO

Kaleido Biosciences, Inc.

Nasdaq

KMDA

Kamada Ltd.

Nasdaq

KNSA

Kiniksa Pharmaceuticals, Ltd.

Nasdaq

KROS

Keros Therapeutics, Inc.

Nasdaq

KRYS

Krystal Biotech, Inc.

Nasdaq

KZR

Kezar Life Sciences, Inc.

Nasdaq

LEGN

Legend Biotech Corporation

Nasdaq

LRMR

Larimar Therapeutics, Inc.

Nasdaq

MDGL

Madrigal Pharmaceuticals, Inc.

Nasdaq

MNOV

MediciNova, Inc.

Nasdaq

MRNS

Marinus Pharmaceuticals, Inc.

Nasdaq

MRSN

Mersana Therapeutics, Inc.

Nasdaq

NK

NantKwest, Inc.

Nasdaq

NKTX

Nkarta, Inc.

Nasdaq

NLTX

Neoleukin Therapeutics, Inc.

Nasdaq

NRIX

Nurix Therapeutics, Inc.

Nasdaq

NVAX

Novavax, Inc.

Nasdaq

NXTC

NextCure, Inc.

Nasdaq

OCUL

Ocular Therapeutix, Inc.

Nasdaq

ODT

Odonate Therapeutics, Inc.

Nasdaq

ORIC

Oric Pharmaceuticals, Inc.

Nasdaq

OVID

Ovid Therapeutics Inc.

Nasdaq

PAHC

Phibro Animal Health Corporation

Nasdaq

PAND

Pandion Therapeutics Inc.

Nasdaq

PASG

Passage Bio, Inc.

Nasdaq

PCVX

Vaxcyte, Inc.

Nasdaq

PLRX

Pliant Therapeutics, Inc.

Nasdaq

PRTK

Paratek Pharmaceuticals, Inc.

Nasdaq

PRVB

Provention Bio, Inc.

Nasdaq

PSTX

Poseida Therapeutics, Inc.

Nasdaq

RAPT

RAPT Therapeutics, Inc.

Nasdaq

RDHL

Redhill Biopharma Ltd.

Nasdaq

REPL

Replimune Group, Inc.

Nasdaq

RLAY

Relay Therapeutics, Inc.

Nasdaq

RLMD

Relmada Therapeutics, Inc.

Nasdaq

RNA

Avidity Biosciences, Inc.

Nasdaq

RPRX

Royalty Pharma plc

Nasdaq

RPTX

Repare Therapeutics Inc.

Nasdaq

RVMD

Revolution Medicines, Inc.

Nasdaq

SELB

Selecta Biosciences, Inc.

Nasdaq

SMMT

Summit Therapeutics Inc.

Nasdaq

SNDX

Syndax Pharmaceuticals, Inc.

Nasdaq

SPRO

Spero Therapeutics, Inc.

Nasdaq

STRO

Sutro Biopharma, Inc.

Nasdaq

SURF

Surface Oncology, Inc.

Nasdaq

SWTX

SpringWorks Therapeutics, Inc.

Nasdaq

TCRR

TCR2 Therapeutics Inc.

Nasdaq

VIE

Viela Bio, Inc.

Nasdaq

VIR

Vir Biotechnology, Inc.

Nasdaq

VSTM

Verastem, Inc.

Nasdaq

VYNE

VYNE Therapeutics Inc.

Nasdaq

XENE

Xenon Pharmaceuticals Inc.

Nasdaq

ZIOP

ZIOPHARM Oncology Inc

Nasdaq

ZNTL

Zentalis Pharmaceuticals, Inc.

As a result of the reconstitution, the following 16 securities will be removed from the Index:

EXCHANGE

SYMBOL

COMPANY NAME

Nasdaq

ADMA

ADMA Biologics Inc

Nasdaq

AMRS

Amyris, Inc.

Nasdaq

AXNX

Axonics Modulation Technologies, Inc.

Nasdaq

CERS

Cerus Corporation

Nasdaq

CRBP

Corbus Pharmaceuticals Holdings, Inc.

Nasdaq

EOLS

Evolus, Inc.

Nasdaq

EYPT

EyePoint Pharmaceuticals, Inc.

Nasdaq

GLYC

GlycoMimetics, Inc.

Nasdaq

GRTS

Gritstone Oncology, Inc.

Nasdaq

LXRX

Lexicon Pharmaceuticals, Inc.

Nasdaq

NVCR

NovoCure Limited

Nasdaq

OPTN

OptiNose, Inc.

Nasdaq

PRQR

ProQR Therapeutics N.V.

Nasdaq

QTRX

Quanterix Corporation

Nasdaq

SLDB

Solid Biosciences Inc.

Nasdaq

TECH

Bio-Techne Corp

About Nasdaq Global Indexes
Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Media Relations Contact
Emily Pan
(646) 637-3964
emily.pan@nasdaq.com

Issuer & Investor Contact
Index Client Services
indexservices@nasdaq.com

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG-